<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18402">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02015910</url>
  </required_header>
  <id_info>
    <org_study_id>MISP-RC50959</org_study_id>
    <nct_id>NCT02015910</nct_id>
  </id_info>
  <brief_title>Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <authority>United States: Federal Government</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the rate of healing as well as percent of
      wounds healed in Type II diabetic patients with chronic foot ulcerations receiving
      sitagliptin versus placebo.

      The hypothesis for this study is that subjects receiving daily doses of sitagliptin in
      combination with their regular antihyperglycemic medications will result in increased
      healing rates as well as a greater number of healed wounds as compared to subjects receiving
      placebo and their regular antihyperglycemic medications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percent Wounds Healed</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare the rate of healing as well as percent of wounds healed in Type II diabetic patients with chronic foot ulcerations receiving sitagliptin versus placebo.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Insulin Dependent Diabetes Mellitus (Type II Diabetes)</condition>
  <arm_group>
    <arm_group_label>Januvia (Sitagliptin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitagliptin 100 mg a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Comparison of Sitagliptin a dipeptidyl-peptidase four (DPP-4) inhibitor 100mg pill with placebo comparator</description>
    <arm_group_label>Januvia (Sitagliptin)</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill manufactured to mimick Sitagliptin 100mg pill.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female age &gt;18

          -  Type II Diabetes with glycated hemoglobin (hemoglobin A1C) of &lt; 11

          -  Currently on an oral hyperglycemic medication other than sitagliptin

          -  A chronic wound defined as the lack of wound healing progress of &lt;15% per     week or
             50% over a month period

          -  Ankle brachial index of &gt; 0.80

          -  Wound located on the foot or ankle (Wagner Grade 1,2)

          -  Able to comply with the requirements of the research trial

        Exclusion Criteria:

          -  Current use of dipeptidyl-peptidase four (DPP-4) inhibitor or glucagon like peptide
             one (GLP-1)agonist

          -  End stage renal disease

          -  Currently enrolled in another research trial that involves treatment of the wound

          -  Active infection of the wound

          -  Wound that probes to bone with osteomyelitis (Wagner Grade 3)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul J Kim, DPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul J Kim, DPM</last_name>
    <phone>202-444-3059</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Medstar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Kim, DPM</last_name>
      <phone>202-444-3059</phone>
    </contact>
    <investigator>
      <last_name>Paul Kim, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 7, 2014</lastchanged_date>
  <firstreceived_date>December 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Georgetown University</investigator_affiliation>
    <investigator_full_name>Paul J. Kim, DPM</investigator_full_name>
    <investigator_title>Doctor of Podiatric Medicine</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sitagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
